Invitae Corporation

Equities

NVTA.Q

US46185L1035

Biotechnology & Medical Research

End-of-day quote OTC Markets 06:00:00 2024-04-17 pm EDT 5-day change 1st Jan Change
0.0034 USD +25.93% Intraday chart for Invitae Corporation +1,033.33% -99.46%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance CI
Invitae Launches Update to Invitae Generation: Clinical Variant Modeling Improves Variant Classification CI
Earnings Flash (NVTA) INVITAE CORPORATION Posts Q4 Revenue $127.8M MT
Invitae Corporation Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023 CI
Bidding Procedure Approved for Invitae Corporation CI
Motion for Joint Administration Approved for Invitae Corporation CI
Invitae gets court approval for five-month bankruptcy sale RE
Global markets live: Airbnb, Sony, Uber, Lyft, Nvidia... Our Logo
Genetic test maker Invitae files for bankruptcy protection in US RE
Motion for Asset Sale Filed by Invitae Corporation CI
Invitae Corporation Lists Estimated Assets In The Range Of $500 Mln -$1 Bln - Court Filing RE
INVITAE CORPORATION LISTS ESTIMATED LIABILITIES IN THE RANGE OF… RE
Genetic test maker Invitae files for voluntary Chapter 11 protection RE
Motion for Joint Administration Filed by Invitae Corporation CI
Invitae Corporation Filed for Bankruptcy CI
Invitae Corporation(OTCPK:NVTA) dropped from S&P Global BMI Index CI
Invitae Corporation(OTCPK:NVTA) dropped from S&P TMI Index CI
Global markets live: BP, Palantir, Infineon, Toyota, UBS... Our Logo
Invitae Corporation May File for Bankruptcy CI
Sector Update: Health Care Stocks Rise Late Afternoon MT
Sector Update: Health Care Stocks Advance Monday Afternoon MT
Invitae to File for Bankruptcy in Coming Weeks MT
Medical test maker Invitae prepares for bankruptcy - WSJ RE
Invitae Collaborates With BridgeBio Pharma for Rare Disease Therapeutics MT
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics CI
Chart Invitae Corporation
More charts
Invitae Corporation is a medical genetics company. The Company is engaged in delivering genetic testing services, digital health solutions, and health data services that support a lifetime of patient care and improved outcomes. It offers genetic testing across multiple clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases and pharmacogenomics. It applies proprietary design, process automation, robotics and bioinformatics software solutions to expand the use and impact of genetic information in sample processing and complex variant interpretation, allowing medical interpretation at scale. The Company also utilizes digital health solutions to improve ease-of-use and to deliver actionable information about risk, prevention, treatment, and monitoring. The Company has served over 3.6 million patients, and over 2.2 million of those patients have made their information available for data sharing.
Related indices
More about the company
  1. Stock Market
  2. Equities
  3. NVTA.Q Stock
  4. News Invitae Corporation
  5. Invitae to File for Bankruptcy in Coming Weeks